KẾT QUẢ HÓA XẠ TRỊ ĐỒNG THỜI PHÁC ĐỒ PACLITAXEL - CARBOPLATIN Ở BỆNH NHÂN UNG THƯ PHỔI LOẠI BIỂU MÔ TUYẾN GIAI ĐOẠN IIIB, IIIC TẠI BỆNH VIỆN HỮU NGHỊ VIỆT TIỆP

Abstract

Objective: To evaluate the outcome of concurrent chemoradiotherapy with paclitaxel - carboplatin regimen in lung adenocarcinoma patients with stage IIIB and IIIC at Viet Tiep Hospital. Subjects and methods: A prospective study with intervention and longitudinal follow-up on 55 lung adenocarcinoma patients with stage IIIB and IIIC treated with concurrent chemoradiotherapy by paclitaxel - carboplatin regimen from October 2020 to September 2024. Results: The disease control rate was 78.2%, of which 37 patients had a partial response (67.3%) and 6 patients (10.9%) had a complete response after concurrent chemoradiotherapy. Total radiation dose ≥ 60 Gy is more effective than total radiation dose < 60 Gy (p < 0.05). Adverse events are common at levels 1 and 2, of which 45.5% of patients experience hematopoietic organ and 21.8% of patients experience pneumonia. Conclusions: Concurrent chemoradiotherapy with paclitaxel - carboplatin regimen gives good results in lung adenocarcinoma patients with stage IIIB and IIIC.